 Immuron Limited NASDAQ: IMRN went up 30 after it announced that it had received 6.2 million from the Department of Defense to conduct clinical research on a dosing regimen for Travelan. This new research agreement with the DoD aims to confirm and test the efficacy of dosing regimens of Travelan in a CHIM controlled human infection ... The post Here is why Immuron is up 30 on Wednesday appeared first on Invezz. 